Sarcopenia, frailty and type 2 diabetes mellitus (Review)

Nishikawa,Hiroki; Fukunishi,Shinya; Asai,Akira; Yokohama,Keisuke; Ohama,Hideko; Nishiguchi,Shuhei; Higuchi,Kazuhide

doi:10.3892/mmr.2021.12494

Sarcopenia, frailty and type 2 diabetes mellitus (Review)

Authors:
- Hiroki Nishikawa
- Shinya Fukunishi
- Akira Asai
- Keisuke Yokohama
- Hideko Ohama
- Shuhei Nishiguchi
- Kazuhide Higuchi
View Affiliations

Affiliations: The Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569‑8686, Japan, The Department of Internal Medicine, Kano General Hospital, Takatsuki, Osaka 531‑0041, Japan
Published online on: October 14, 2021 https://doi.org/10.3892/mmr.2021.12494
Article Number: 854

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Skeletal muscle is the largest and most energy‑consuming organ in the human body, which plays an important role in energy metabolism and glucose uptake. There is a notable decrease in glucose uptake in the skeletal muscle of patients with type 2 diabetes mellitus (DM). Endurance exercise can reduce hyperglycemia and improve insulin resistance in patients with type 2 DM. Insulin exerts a variety of effects, many of which are mediated by Akt, including increasing glucose uptake, promoting glycogen synthesis and inhibiting glycogen degradation, increasing free fatty acid uptake, increasing protein synthesis, promoting muscle hypertrophy and inhibiting protein degradation. Skeletal muscle mass progressively declines with aging, resulting in loss of muscle strength and physical function. Sarcopenia is a syndrome characterized by loss of skeletal muscle mass and muscle weakness or loss of physical function, and frailty is another syndrome that has received great interest in recent years. Decreased organ function results in vulnerability to external stress. Frailty is associated with falls, fractures and hospitalization; however, there is the reversibility of returning to a healthy state with appropriate interventions. Frailty is classified into three subgroups: Physical frailty, social frailty and cognitive frailty, whereby sarcopenia is the main component of physical frailty. The present review discusses the associations between sarcopenia, frailty and type 2 DM based on current evidence.

View Figures

View References

1	Gibbons A: HUMAN EVOLUTION. Why humans are the high-energy apes. Science. 352:6392016. View Article : Google Scholar : PubMed/NCBI
2	Roth J, Szulc AL and Danoff A: Energy, evolution, and human diseases: An overview. Am J Clin Nutr. 93:875S–883S. 2011. View Article : Google Scholar : PubMed/NCBI
3	Evans PL, McMillin SL, Weyrauch LA and Witczak CA: Regulation of skeletal muscle glucose transport and glucose metabolism by exercise training. Nutrients. 11:24322019. View Article : Google Scholar : PubMed/NCBI
4	Seo JA, Kang MC, Yang WM, Hwang WM, Kim SS, Hong SH, Heo JI, Vijyakumar A, Pereira de ML, Uner A, et al: Apolipoprotein J is a hepatokine regulating muscle glucose metabolism and insulin sensitivity. Nat Commun. 11:20242020. View Article : Google Scholar : PubMed/NCBI
5	Severinsen MCK and Pedersen BK: Muscle-organ crosstalk: The emerging roles of myokines. Endocr Rev. 41:594–609. 2020. View Article : Google Scholar : PubMed/NCBI
6	Mukund K and Subramaniam S: Skeletal muscle: A review of molecular structure and function, in health and disease. Wiley Interdiscip Rev Syst Biol Med. 12:e14622020. View Article : Google Scholar : PubMed/NCBI
7	Jackson AS, Janssen I, Sui X, Church TS and Blair SN: Longitudinal changes in body composition associated with healthy ageing: Men, aged 20–96 years. Br J Nutr. 107:1085–1091. 2012. View Article : Google Scholar : PubMed/NCBI
8	Schosserer M, Grillari J, Wolfrum C and Scheideler M: Age-induced changes in white, brite, and brown adipose depots: A mini-review. Gerontology. 64:229–236. 2018. View Article : Google Scholar : PubMed/NCBI
9	Wu H and Ballantyne CM: Skeletal muscle inflammation and insulin resistance in obesity. J Clin Invest. 127:43–54. 2017. View Article : Google Scholar : PubMed/NCBI
10	Kawada T: Basal metabolic rate parameters, sarcopenia, and frailty in older males. J Am Med Dir Assoc. 20:9192019. View Article : Google Scholar : PubMed/NCBI
11	Zampino M, Semba RD, Adelnia F, Spencer RG, Fishbein KW, Schrack JA, Simonsick EM and Ferrucci L: Greater skeletal muscle oxidative capacity is associated with higher resting metabolic rate: Results from the baltimore longitudinal study of aging. J Gerontol A Biol Sci Med Sci. 75:2262–2268. 2020. View Article : Google Scholar : PubMed/NCBI
12	Saltiel AR: Insulin signaling in health and disease. J Clin Invest. 131:e1422412021. View Article : Google Scholar : PubMed/NCBI
13	Kadowaki T, Ueki K, Yamauchi T and Kubota N: SnapShot: Insulin signaling pathways. Cell. 148:624–624.e1. 2012. View Article : Google Scholar : PubMed/NCBI
14	Burke LM, Kiens B and Ivy JL: Carbohydrates and fat for training and recovery. J Sports Sci. 22:15–30. 2004. View Article : Google Scholar : PubMed/NCBI
15	Volek JS, Noakes T and Phinney SD: Rethinking fat as a fuel for endurance exercise. Eur J Sport Sci. 15:13–20. 2015. View Article : Google Scholar : PubMed/NCBI
16	Sato T, Ito Y and Nagasawa T: Regulation of skeletal muscle protein degradation and synthesis by oral administration of lysine in rats. J Nutr Sci Vitaminol (Tokyo). 59:412–419. 2013. View Article : Google Scholar : PubMed/NCBI
17	Sato T, Ito Y and Nagasawa T: L-Lysine suppresses myofibrillar protein degradation and autophagy in skeletal muscles of senescence-accelerated mouse prone 8. Biogerontology. 18:85–95. 2017. View Article : Google Scholar : PubMed/NCBI
18	Kamei Y, Hatazawa Y, Uchitomi R, Yoshimura R and Miura S: Regulation of skeletal muscle function by amino acids. Nutrients. 12:2612020. View Article : Google Scholar : PubMed/NCBI
19	Kitamura A, Seino S, Abe T, Nofuji Y, Yokoyama Y, Amano H, Nishi M, Taniguchi Y, Narita M, Fujiwara Y and Shinkai S: Sarcopenia: prevalence, associated factors, and the risk of mortality and disability in Japanese older adults. J Cachexia Sarcopenia Muscle. 12:30–38. 2021. View Article : Google Scholar : PubMed/NCBI
20	Nishikawa H, Fukunishi S, Asai A, Nishiguchi S and Higuchi K: Sarcopenia and frailty in liver Cirrhosis. Life (Basel). 11:3992021.PubMed/NCBI
21	Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, et al: Sarcopenia: European consensus on definition and diagnosis: Report of the European working group on sarcopenia in older people. Age Ageing. 39:412–423. 2010. View Article : Google Scholar : PubMed/NCBI
22	Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, et al: Sarcopenia in Asia: Consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc. 15:95–101. 2014. View Article : Google Scholar : PubMed/NCBI
23	Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K and Nishiguchi S: Japan society of hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 46:951–963. 2016. View Article : Google Scholar : PubMed/NCBI
24	Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, et al: Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing. 48:16–31. 2019. View Article : Google Scholar : PubMed/NCBI
25	Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, et al: Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 21:300–307.e2. 2020. View Article : Google Scholar : PubMed/NCBI
26	Sampaio RAC, Sewo Sampaio PY, Uchida MC and Arai H: Management of dynapenia, sarcopenia, and frailty: The role of physical exercise. J Aging Res. 2020:81867692020. View Article : Google Scholar : PubMed/NCBI
27	Satake S and Arai H: Implications of frailty screening in clinical practice. Curr Opin Clin Nutr Metab Care. 20:4–10. 2017. View Article : Google Scholar : PubMed/NCBI
28	Sugimoto K, Rakugi H, Kojima T, Ishii S, Akishita M, Tamura Y, Araki A, Kozaki K, Senda K, Fukuoka H, et al: Chapter 4 Frailty and specific diseases. Geriatr Gerontol Int. 20 (Suppl 1):S25–S37. 2020. View Article : Google Scholar
29	Mesinovic J, Zengin A, De Courten B, Ebeling PR and Scott D: Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship. Diabetes Metab Syndr Obes. 12:1057–1072. 2019. View Article : Google Scholar : PubMed/NCBI
30	DeFronzo RA: Lilly lecture 1987. The triumvirate: Beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 37:667–687. 1988. View Article : Google Scholar : PubMed/NCBI
31	Bu L, Cao X, Zhang Z, Wu H, Guo R and Ma M: Decreased secretion of tumor necrosis factor-α attenuates macrophages-induced insulin resistance in skeletal muscle. Life Sci. 244:1173042020. View Article : Google Scholar : PubMed/NCBI
32	Love KM, Liu J, Regensteiner JG, Reusch JEB and Liu Z: GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. J Diabetes. 12:488–498. 2020. View Article : Google Scholar : PubMed/NCBI
33	Nishikawa H and Osaki Y: Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. Hepatol Res. 44:149–158. 2014. View Article : Google Scholar : PubMed/NCBI
34	Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Yuri Y, Takata R, Hasegawa K, Nakano C, et al: Development of a simple predictive model for decreased skeletal muscle mass in patients with compensated chronic liver disease. Hepatol Res. 47:1223–1234. 2017. View Article : Google Scholar : PubMed/NCBI
35	Nishikawa H, Yoh K, Enomoto H, Iwata Y, Sakai Y, Kishino K, Shimono Y, Ikeda N, Takashima T, Aizawa N, et al: Sarcopenia and frailty in chronic liver damage: Common and different points. In Vivo. 34:2549–2559. 2020. View Article : Google Scholar : PubMed/NCBI
36	Richter EA and Hargreaves M: Exercise, GLUT4, and skeletal muscle glucose uptake. Physiol Rev. 93:993–1017. 2013. View Article : Google Scholar : PubMed/NCBI
37	Flores-Opazo M, McGee SL and Hargreaves M: Exercise and GLUT4. Exerc Sport Sci Rev. 48:110–118. 2020. View Article : Google Scholar : PubMed/NCBI
38	Hood DA, Memme JM, Oliveira AN and Triolo M: Maintenance of skeletal muscle mitochondria in health, exercise, and aging. Annu Rev Physiol. 81:19–41. 2019. View Article : Google Scholar : PubMed/NCBI
39	Memme JM, Erlich AT, Phukan G and Hood DA: Exercise and mitochondrial health. J Physiol. 599:803–817. 2021. View Article : Google Scholar : PubMed/NCBI
40	Hatazawa Y, Tadaishi M, Nagaike Y, Morita A, Ogawa Y, Ezaki O, Takai-Igarashi T, Kitaura Y, Shimomura Y, Kamei Y and Miura S: PGC-1α-mediated branched-chain amino acid metabolism in the skeletal muscle. PLoS One. 9:e910062014. View Article : Google Scholar : PubMed/NCBI
41	Schnyder S and Handschin C: Skeletal muscle as an endocrine organ: PGC-1α, myokines and exercise. Bone. 80:115–125. 2015. View Article : Google Scholar : PubMed/NCBI
42	Norheim F, Langleite TM, Hjorth M, Holen T, Kielland A, Stadheim HK, Gulseth HL, Birkeland KI, Jensen J and Drevon CA: The effects of acute and chronic exercise on PGC-1α, irisin and browning of subcutaneous adipose tissue in humans. FEBS J. 281:739–749. 2014. View Article : Google Scholar : PubMed/NCBI
43	Booth FW, Ruegsegger GN, Toedebusch RG and Yan Z: Endurance exercise and the regulation of skeletal muscle metabolism. Prog Mol Biol Transl Sci. 135:129–151. 2015. View Article : Google Scholar : PubMed/NCBI
44	Islam H, Hood DA and Gurd BJ: Looking beyond PGC-1α: Emerging regulators of exercise-induced skeletal muscle mitochondrial biogenesis and their activation by dietary compounds. Appl Physiol Nutr Metab. 45:11–23. 2020. View Article : Google Scholar : PubMed/NCBI
45	Jang C, Oh SF, Wada S, Rowe GC, Liu L, Chan MC, Rhee J, Hoshino A, Kim B, Ibrahim A, et al: A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat Med. 22:421–426. 2016. View Article : Google Scholar : PubMed/NCBI
46	Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu PH, et al: Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab. 1:259–271. 2005. View Article : Google Scholar : PubMed/NCBI
47	Cretoiu D, Pavelescu L, Duica F, Radu M, Suciu N and Cretoiu SM: Myofibers. Adv Exp Med Biol. 1088:23–46. 2018. View Article : Google Scholar : PubMed/NCBI
48	Drake JC and Yan Z: Precision remodeling: How exercise improves mitochondrial quality in myofibers. Curr Opin Physiol. 10:96–101. 2019. View Article : Google Scholar : PubMed/NCBI
49	Hickey MS, Carey JO, Azevedo JL, Houmard JA, Pories WJ, Israel RG and Dohm GL: Skeletal muscle fiber composition is related to adiposity and in vitro glucose transport rate in humans. Am J Physiol. 268((3 Pt 1)): E453–E457. 1995.PubMed/NCBI
50	Märin P, Krotkiewski M, Andersson B and Björntorp P: Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care. 17:382–386. 1994. View Article : Google Scholar : PubMed/NCBI
51	Kaji A, Hashimoto Y, Kobayashi Y, Sakai R, Okamura T, Miki A, Hamaguchi M, Kuwahata M, Yamazaki M and Fukui M: Sarcopenia is associated with tongue pressure in older patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort study. Geriatr Gerontol Int. 19:153–158. 2019. View Article : Google Scholar : PubMed/NCBI
52	Sazlina SG, Lee PY, Chan YM, A Hamid MS and Tan NC: The prevalence and factors associated with sarcopenia among community living elderly with type 2 diabetes mellitus in primary care clinics in Malaysia. PLoS One. 15:e02332992020. View Article : Google Scholar : PubMed/NCBI
53	Bouchi R, Fukuda T, Takeuchi T, Minami I, Yoshimoto T and Ogawa Y: Sarcopenia is associated with incident albuminuria in patients with type 2 diabetes: A retrospective observational study. J Diabetes Investig. 8:783–787. 2017. View Article : Google Scholar : PubMed/NCBI
54	Hashimoto Y, Kaji A, Sakai R, Hamaguchi M, Okada H, Ushigome E, Asano M, Yamazaki M and Fukui M: Sarcopenia is associated with blood pressure variability in older patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort study. Geriatr Gerontol Int. 18:1345–1349. 2018. View Article : Google Scholar : PubMed/NCBI
55	Okamura T, Mik A, Hashimoto Y, Kaji A, Sakai R, Osaka T, Hamaguchi M, Yamazaki M and Fukui M: Deficiency of energy intake rather than protein is associated with sarcopenia in early patients with type 2 diabetes: A cross-sectional study of the KAMOGAWA-DM cohort. J Diabetes. 11:477–483. 2019. View Article : Google Scholar : PubMed/NCBI
56	Okamura T, Hashimoto Y, Miki A, Kaji A, Sakai R, Iwai K, Osaka T, Kitagawa N, Ushigome E, Hamaguchi M, et al: High brain natriuretic peptide is associated with sarcopenia in patients with type 2 diabetes: A cross-sectional study of KAMOGAWA-DM cohort study. Endocr J. 66:369–377. 2019. View Article : Google Scholar : PubMed/NCBI
57	Bouchi R, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T and Ogawa Y: Insulin treatment attenuates decline of muscle mass in Japanese patients with type 2 diabetes. Calcif Tissue Int. 101:1–8. 2017. View Article : Google Scholar : PubMed/NCBI
58	Cui M, Gang X and Wang G, Xiao X, Li Z, Jiang Z and Wang G: A cross-sectional study: Associations between sarcopenia and clinical characteristics of patients with type 2 diabetes. Medicine (Baltimore). 99:e187082020. View Article : Google Scholar : PubMed/NCBI
59	Sugimoto K, Tabara Y, Ikegami H, Takata Y, Kamide K, Ikezoe T, Kiyoshige E, Makutani Y, Onuma H, Gondo Y, et al: Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: The multicenter study for clarifying evidence for sarcopenia in patients with diabetes mellitus. J Diabetes Investig. 10:1471–1479. 2019. View Article : Google Scholar : PubMed/NCBI
60	Fung FY, Koh YLE, Malhotra R, Ostbye T, Lee PY, Shariff Ghazali S and Tan NC: Prevalence of and factors associated with sarcopenia among multi-ethnic ambulatory older Asians with type 2 diabetes mellitus in a primary care setting. BMC Geriatr. 19:1222019. View Article : Google Scholar : PubMed/NCBI
61	Mori H, Kuroda A, Ishizu M, Ohishi M, Takashi Y, Otsuka Y, Taniguchi S, Tamaki M, Kurahashi K, Yoshida S, et al: Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes. J Diabetes Investig. 10:1332–1340. 2019. View Article : Google Scholar : PubMed/NCBI
62	Ida S, Murata K, Nakadachi D, Ishihara Y, Imataka K, Uchida A, Monguchi K, Kaneko R, Fujiwara R and Takahashi H: Association between dynapenia and decline in higher-level functional capacity in older men with diabetes. Geriatr Gerontol Int. 18:1393–1397. 2018. View Article : Google Scholar : PubMed/NCBI
63	Murai J, Nishizawa H, Otsuka A, Fukuda S, Tanaka Y, Nagao H, Sakai Y, Suzuki M, Yokota S, Tada H, et al: Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation. Cardiovasc Diabetol. 17:1122018. View Article : Google Scholar : PubMed/NCBI
64	Osaka T, Hamaguchi M, Hashimoto Y, Ushigome E, Tanaka M, Yamazaki M and Fukui M: Decreased the creatinine to cystatin C ratio is a surrogate marker of sarcopenia in patients with type 2 diabetes. Diabetes Res Clin Pract. 139:52–58. 2018. View Article : Google Scholar : PubMed/NCBI
65	Fukuda T, Bouchi R, Takeuchi T, Tsujimoto K, Minami I, Yoshimoto T and Ogawa Y: Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: A retrospective observational study. Cardiovasc Diabetol. 17:552018. View Article : Google Scholar : PubMed/NCBI
66	Fukuoka Y, Narita T, Fujita H, Morii T, Sato T, Sassa MH and Yamada Y: Importance of physical evaluation using skeletal muscle mass index and body fat percentage to prevent sarcopenia in elderly Japanese diabetes patients. J Diabetes Investig. 10:322–330. 2019. View Article : Google Scholar : PubMed/NCBI
67	Murata Y, Kadoya Y, Yamada S and Sank T: Sarcopenia in elderly patients with type 2 diabetes mellitus: Prevalence and related clinical factors. Diabetol Int. 9:136–142. 2017. View Article : Google Scholar : PubMed/NCBI
68	Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, de Rekeneire N, Harris TB, Kritchevsky S, Tylavsky FA, Nevitt M, et al: Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care. 32:1993–1997. 2009. View Article : Google Scholar : PubMed/NCBI
69	Anbalagan VP, Venkataraman V, Pradeepa R, Deepa M, Anjana RM and Mohan V: The prevalence of presarcopenia in Asian Indian individuals with and without type 2 diabetes. Diabetes Technol Ther. 15:768–775. 2013. View Article : Google Scholar : PubMed/NCBI
70	Leenders M, Verdijk LB, van der Hoeven L, Adam JJ, van Kranenbur J, Nilwik R and van Loon LJ: Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc. 14:585–592. 2013. View Article : Google Scholar : PubMed/NCBI
71	Srikanthan P, Hevener AL and Karlamangla AS: Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: Findings from the National health and nutrition examination survey III. PLoS One. 5:e108052010. View Article : Google Scholar : PubMed/NCBI
72	Sanada K, Miyachi M, Tanimoto M, Yamamoto K, Murakami H, Okumura S, Gando Y, Suzuki K, Tabata I and Higuchi M: A cross-sectional study of sarcopenia in Japanese men and women: Reference values and association with cardiovascular risk factors. Eur J Appl Physiol. 110:57–65. 2010. View Article : Google Scholar : PubMed/NCBI
73	Lee CG, Boyko EJ, Strotmeyer ES, Lewis CE, Cawthon PM, Hoffman AR, Everson-Rose SA, Barrett-Connor E and Orwoll ES; Osteoporotic Fractures in Men Study Research Group, : Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. J Am Geriatr Soc. 59:1217–1224. 2011. View Article : Google Scholar : PubMed/NCBI
74	Araki A and Ito H: Diabetes mellitus and geriatric syndromes. Geriatr Gerontol Int. 9:105–114. 2009. View Article : Google Scholar : PubMed/NCBI
75	Kim TN, Park MS, Yang SJ, Yoo HJ, Kang HJ, Song W, Seo JA, Kim SG, Kim NH, Baik SH, et al: Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: The Korean sarcopenic obesity study (KSOS). Diabetes Care. 33:1497–1499. 2010. View Article : Google Scholar : PubMed/NCBI
76	Hirata Y, Nomura K, Senga Y, Okada Y, Kobayashi K, Okamoto S, Minokoshi Y, Imamura M, Takeda S, Hosooka T and Ogawa W: Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis. JCI Insight. 4:e1249522019. View Article : Google Scholar : PubMed/NCBI
77	Varshavsky A: The ubiquitin system, autophagy, and regulated protein degradation. Annu Rev Biochem. 86:123–128. 2017. View Article : Google Scholar : PubMed/NCBI
78	Sasaki T: Sarcopenia, frailty circle and treatment with sodium-glucose cotransporter 2 inhibitors. J Diabetes Investig. 10:193–195. 2019. View Article : Google Scholar : PubMed/NCBI
79	Sasaki T, Sugawara M and Fukuda M: Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: The components of weight loss in Japanese patients with type 2 diabetes mellitus) study. J Diabetes Investig. 10:108–117. 2019. View Article : Google Scholar : PubMed/NCBI
80	Chen F, Xu S, Wang Y, Chen F, Cao L, Liu T, Huang T, Wei Q, Ma G, Zhao Y and Wang D: Risk factors for sarcopenia in the elderly with type 2 diabetes mellitus and the effect of metformin. J Diabetes Res. 2020:39504042020. View Article : Google Scholar : PubMed/NCBI
81	Laksmi PW, Setiati S, Tamin TZ, Soewondo P, Rochmah W, Nafrialdi N and Prihartono J: Effect of metformin on handgrip strength, gait speed, myostatin serum level, and health-related quality of life: A double blind randomized controlled trial among non-diabetic pre-frail elderly patients. Acta Med Indones. 49:118–127. 2017.PubMed/NCBI
82	Yang Y, Liao Z and Xiao Q: Metformin ameliorates skeletal muscle atrophy in Grx1 KO mice by regulating intramuscular lipid accumulation and glucose utilization. Biochem Biophys Res Commun. 533:1226–1232. 2020. View Article : Google Scholar : PubMed/NCBI
83	Pirkmajer S, Petrič M and Chibalin AV: The role of AMPK in regulation of Na⁺, K⁺-ATPase in skeletal muscle: Does the gauge always plug the sink? J Muscle Res Cell Motil. 42:77–97. 2021. View Article : Google Scholar : PubMed/NCBI
84	McGee SL and Hargreaves M: Exercise adaptations: Molecular mechanisms and potential targets for therapeutic benefit. Nat Rev Endocrinol. 16:495–505. 2020. View Article : Google Scholar : PubMed/NCBI
85	LaMoia TE and Shulman GI: Cellular and molecular mechanisms of metformin action. Endocr Rev. 42:77–96. 2021. View Article : Google Scholar : PubMed/NCBI
86	Lee CG, Boyko EJ, Barrett-Connor E, Miljkovic I, Hoffman AR, Everson-Rose SA, Lewis CE, Cawthon PM, Strotmeyer ES and Orwoll ES; Osteoporotic Fractures in Men (MrOS) Study Research Group, : Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care. 34:2381–2386. 2011. View Article : Google Scholar : PubMed/NCBI
87	Clegg A, Young J, Iliffe S, Rikkert MO and Rockwood K: Frailty in elderly people. Lancet. 381:752–762. 2013. View Article : Google Scholar : PubMed/NCBI
88	Morley JE, Malmstrom TK, Rodriguez-Mañas L and Sinclair AJ: Frailty, Sarcopenia and diabetes. J Am Med Dir Assoc. 15:853–859. 2014. View Article : Google Scholar : PubMed/NCBI
89	García-Esquinas E, Graciani A, Guallar-Castillón P, López-García E, Rodríguez-Mañas L and Rodríguez-Artalejo F: Diabetes and risk of frailty and its potential mechanisms: A prospective cohort study of older adults. J Am Med Dir Assoc. 16:748–754. 2015. View Article : Google Scholar : PubMed/NCBI
90	Espinoza SE, Jung I and Hazuda H: Frailty transitions in the San Antonio longitudinal study of aging. J Am Geriatr Soc. 60:652–660. 2012. View Article : Google Scholar : PubMed/NCBI
91	Barzilay JI, Blaum C, Moore T, Xue QL, Hirsch CH, Walston JD and Fried LP: Insulin resistance and inflammation as precursors of frailty: The cardiovascular health study. Arch Intern Med. 167:635–641. 2007. View Article : Google Scholar : PubMed/NCBI
92	Pérez-Tasigchana RF, León-Muñoz LM, Lopez-Garcia E, Gutierrez-Fisac JL, Laclaustra M, Rodríguez-Artalejo F and Guallar-Castillón P: Metabolic syndrome and insulin resistance are associated with frailty in older adults: A prospective cohort study. Age Ageing. 46:807–812. 2017. View Article : Google Scholar : PubMed/NCBI
93	Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, Gottdiener J and Fried LP; Cardiovascular Health Study, : Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: Results from the cardiovascular health study. Arch Intern Med. 162:2333–2341. 2002. View Article : Google Scholar : PubMed/NCBI
94	Kalyani RR, Varadhan R, Weiss CO, Fried LP and Cappola AR: Frailty status and altered glucose-insulin dynamics. J Gerontol A Biol Sci Med Sci. 67:1300–1306. 2012. View Article : Google Scholar : PubMed/NCBI
95	Veronese N, Stubbs B, Fontana L, Trevisan C, Bolzetta F, De Rui M, Sartori L, Musacchio E, Zambon S, Maggi S, et al: Frailty is associated with an increased risk of incident type 2 diabetes in the elderly. J Am Med Dir Assoc. 17:902–907. 2016. View Article : Google Scholar : PubMed/NCBI
96	Li G, Prior JC, Leslie WD, Thabane L, Papaioannou A, Josse RG, Kaiser SM, Kovacs CS, Anastassiades T, Towheed T, et al: Frailty and risk of fractures in patients with Type 2 Diabetes. Diabetes Care. 42:507–513. 2019. View Article : Google Scholar : PubMed/NCBI
97	Tamura H, Miyamoto T, Tamaki A, Nawa G and Konya H: Osteoporosis complication is a risk factor for frailty in females with type 2 diabetes mellitus. J Phys Ther Sci. 31:621–624. 2019. View Article : Google Scholar : PubMed/NCBI
98	Chao CT, Wang J and Chien KL; COhort of GEriatric Nephrology in NTUH (COGENT) study group, : Both pre-frailty and frailty increase healthcare utilization and adverse health outcomes in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 17:1302018. View Article : Google Scholar : PubMed/NCBI
99	Blaum CS, Xue QL, Tian J, Semba RD, Fried LP and Walston J: Is hyperglycemia associated with frailty status in older women? J Am Geriatr Soc. 57:840–847. 2009. View Article : Google Scholar : PubMed/NCBI
100	Kalyani RR, Tian J, Xue QL, Walston J, Cappola AR, Fried LP, Brancati FL and Blaum CS: Hyperglycemia and incidence of frailty and lower extremity mobility limitations in older women. J Am Geriatr Soc. 60:1701–1707. 2012. View Article : Google Scholar : PubMed/NCBI
101	Zaslavsky O, Walker RL, Crane PK, Gray SL and Larson EB: glucose levels and risk of frailty. J Gerontol A Biol Sci Med Sci. 71:1223–1229. 2016. View Article : Google Scholar : PubMed/NCBI
102	Yanagita I, Fujihara Y, Eda T, Tajima M, Yonemura K, Kawajiri T, Yamaguchi N, Asakawa H, Nei Y, Kayashima Y, et al: Low glycated hemoglobin level is associated with severity of frailty in Japanese elderly diabetes patients. J Diabetes Investig. 9:419–425. 2018. View Article : Google Scholar : PubMed/NCBI
103	Yau CK, Eng C, Cenzer IS, Boscardin WJ, Rice-Trumble K and Lee SJ: Glycosylated hemoglobin and functional decline in community-dwelling nursing home-eligible elderly adults with diabetes mellitus. J Am Geriatr Soc. 60:1215–1221. 2012. View Article : Google Scholar : PubMed/NCBI